Greg Harrison
Stock Analyst at B of A Securities
(4.47)
# 315
Out of 4,981 analysts
101
Total ratings
61.04%
Success rate
17.31%
Average return
Main Sectors:
Stocks Rated by Greg Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Maintains: Neutral | $314 → $463 | $405.02 | +14.32% | 5 | Sep 2, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $38 → $43 | $37.10 | +15.90% | 2 | Aug 28, 2025 | |
| TVTX Travere Therapeutics | Maintains: Sector Outperform | $30 → $31 | $23.47 | +32.08% | 6 | Aug 7, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Sector Outperform | $22 → $20 | $12.81 | +56.13% | 2 | Aug 6, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Sector Outperform | $55 → $57 | $51.21 | +11.31% | 7 | Aug 6, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Sector Perform | $442 → $438 | $394.53 | +11.02% | 7 | Aug 5, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Sector Outperform | $342 → $450 | $465.89 | -3.41% | 6 | Aug 1, 2025 | |
| AGIO Agios Pharmaceuticals | Maintains: Sector Outperform | $71 → $65 | $36.77 | +76.77% | 7 | Jul 28, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Neutral | $9 → $4 | $3.16 | +26.58% | 8 | Jul 25, 2025 | |
| GOSS Gossamer Bio | Initiates: Sector Outperform | $11 | $3.46 | +217.92% | 1 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $32 → $35 | $17.32 | +102.08% | 2 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $65 → $55 | $23.77 | +131.38% | 3 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $36 → $37 | $25.99 | +42.36% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $41 → $26 | $15.74 | +65.18% | 6 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $28 → $20 | $24.85 | -19.52% | 4 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $4 → $1.5 | $1.27 | +18.11% | 3 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $40 | $20.60 | +94.17% | 5 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $73 → $75 | $59.80 | +25.42% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $18 | $13.35 | +34.83% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $89 → $91 | $11.42 | +696.85% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $23.46 | -48.85% | 3 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $5 → $1.5 | $0.50 | +197.09% | 1 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $15 | $2.69 | +457.62% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $3 | $4.16 | -27.88% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $1.35 | +5,085.19% | 1 | Sep 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $54 | $18.29 | +195.24% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $270 → $90 | $48.68 | +84.88% | 5 | Mar 14, 2022 |
United Therapeutics
Sep 2, 2025
Maintains: Neutral
Price Target: $314 → $463
Current: $405.02
Upside: +14.32%
Mineralys Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $38 → $43
Current: $37.10
Upside: +15.90%
Travere Therapeutics
Aug 7, 2025
Maintains: Sector Outperform
Price Target: $30 → $31
Current: $23.47
Upside: +32.08%
Ocular Therapeutix
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $22 → $20
Current: $12.81
Upside: +56.13%
BridgeBio Pharma
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $55 → $57
Current: $51.21
Upside: +11.31%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Sector Perform
Price Target: $442 → $438
Current: $394.53
Upside: +11.02%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Sector Outperform
Price Target: $342 → $450
Current: $465.89
Upside: -3.41%
Agios Pharmaceuticals
Jul 28, 2025
Maintains: Sector Outperform
Price Target: $71 → $65
Current: $36.77
Upside: +76.77%
Rocket Pharmaceuticals
Jul 25, 2025
Downgrades: Neutral
Price Target: $9 → $4
Current: $3.16
Upside: +26.58%
Gossamer Bio
Jul 14, 2025
Initiates: Sector Outperform
Price Target: $11
Current: $3.46
Upside: +217.92%
Jul 2, 2025
Maintains: Sector Outperform
Price Target: $32 → $35
Current: $17.32
Upside: +102.08%
Jun 2, 2025
Maintains: Sector Outperform
Price Target: $65 → $55
Current: $23.77
Upside: +131.38%
May 28, 2025
Maintains: Sector Outperform
Price Target: $36 → $37
Current: $25.99
Upside: +42.36%
May 12, 2025
Maintains: Sector Outperform
Price Target: $41 → $26
Current: $15.74
Upside: +65.18%
May 8, 2025
Maintains: Sector Perform
Price Target: $28 → $20
Current: $24.85
Upside: -19.52%
May 8, 2025
Downgrades: Sector Perform
Price Target: $4 → $1.5
Current: $1.27
Upside: +18.11%
Mar 10, 2025
Upgrades: Sector Outperform
Price Target: $40
Current: $20.60
Upside: +94.17%
Mar 3, 2025
Maintains: Sector Outperform
Price Target: $73 → $75
Current: $59.80
Upside: +25.42%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $18
Current: $13.35
Upside: +34.83%
Jun 13, 2023
Maintains: Buy
Price Target: $89 → $91
Current: $11.42
Upside: +696.85%
May 1, 2023
Upgrades: Neutral
Price Target: $9 → $12
Current: $23.46
Upside: -48.85%
Apr 28, 2023
Downgrades: Underperform
Price Target: $5 → $1.5
Current: $0.50
Upside: +197.09%
Nov 18, 2022
Maintains: Neutral
Price Target: $18 → $15
Current: $2.69
Upside: +457.62%
Nov 8, 2022
Downgrades: Underperform
Price Target: $3
Current: $4.16
Upside: -27.88%
Sep 29, 2022
Initiates: Buy
Price Target: $70
Current: $1.35
Upside: +5,085.19%
Mar 16, 2022
Maintains: Buy
Price Target: $67 → $54
Current: $18.29
Upside: +195.24%
Mar 14, 2022
Downgrades: Underperform
Price Target: $270 → $90
Current: $48.68
Upside: +84.88%